These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25452003)

  • 1. ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.
    Ye L; Hu B; El-Badri F; Hudson BM; Phuan PW; Verkman AS; Tantillo DJ; Kurth MJ
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5840-5844. PubMed ID: 25452003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.
    Ye L; Knapp JM; Sangwung P; Fettinger JC; Verkman AS; Kurth MJ
    J Med Chem; 2010 May; 53(9):3772-81. PubMed ID: 20373765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
    Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview on chemical structures as ΔF508-CFTR correctors.
    Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
    Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bithiazole correctors rescue CFTR mutants by two different mechanisms.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2013 Aug; 52(31):5161-3. PubMed ID: 23865422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.
    Pedemonte N; Lukacs GL; Du K; Caci E; Zegarra-Moran O; Galietta LJ; Verkman AS
    J Clin Invest; 2005 Sep; 115(9):2564-71. PubMed ID: 16127463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy.
    Yu GJ; Yoo CL; Yang B; Lodewyk MW; Meng L; El-Idreesy TT; Fettinger JC; Tantillo DJ; Verkman AS; Kurth MJ
    J Med Chem; 2008 Oct; 51(19):6044-54. PubMed ID: 18788728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis.
    Donald MB; Rodriguez KX; Shay H; Phuan PW; Verkman AS; Kurth MJ
    Bioorg Med Chem; 2012 Sep; 20(17):5247-53. PubMed ID: 22841006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
    Wang Y; Loo TW; Bartlett MC; Clarke DM
    J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
    Loo TW; Bartlett MC; Clarke DM
    Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional fluorescently labeled bithiazole ΔF508-CFTR corrector imaged in whole body slices in mice.
    Davison HR; Taylor S; Drake C; Phuan PW; Derichs N; Yao C; Jones EF; Sutcliffe J; Verkman AS; Kurth MJ
    Bioconjug Chem; 2011 Dec; 22(12):2593-9. PubMed ID: 22034937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
    Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
    Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
    Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.
    Phuan PW; Veit G; Tan JA; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2015 Oct; 88(4):791-9. PubMed ID: 26245207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain.
    Odolczyk N; Fritsch J; Norez C; Servel N; da Cunha MF; Bitam S; Kupniewska A; Wiszniewski L; Colas J; Tarnowski K; Tondelier D; Roldan A; Saussereau EL; Melin-Heschel P; Wieczorek G; Lukacs GL; Dadlez M; Faure G; Herrmann H; Ollero M; Becq F; Zielenkiewicz P; Edelman A
    EMBO Mol Med; 2013 Oct; 5(10):1484-501. PubMed ID: 23982976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
    Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
    Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein.
    Knapp JM; Wood AB; Phuan PW; Lodewyk MW; Tantillo DJ; Verkman AS; Kurth MJ
    J Med Chem; 2012 Feb; 55(3):1242-51. PubMed ID: 22214395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.